Palvella Therapeutics Company Description

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Palvella Therapeutics, Inc.

Country	United States
Industry	Biological Products, Except Diagnostic Substances
Employees	14
CEO	Wesley Kaupinen

Contact Details

Address: 125 Strafford Avenue Wayne, Nevada 19087 United States
Phone	484 253 1461
Website	palvellatx.com

Stock Details

Ticker Symbol	PI6
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Wesley Kaupinen	Chief Executive Officer
Matthew Korenberg	Chief Financial Officer
Kathleen Goin	Chief Operating Officer